Halozyme Therapeutics

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor. In addition to our proprietary product portfolio, Halozyme has value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for our ENHANZE™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. We are headquartered in San Diego.

Type
Public
HQ
San Diego, US
Founded
1998
Employees
216 (est)+22%
Halozyme Therapeutics was founded in 1998 and is headquartered in San Diego, US

Halozyme Therapeutics Locations

San Diego, US

Halozyme Therapeutics Metrics

Halozyme Therapeutics Summary

Market capitalization

$1.47 B

Closing share price

$11.9
Halozyme Therapeutics's latest market capitalization is $1.47 B.

Halozyme Therapeutics Market Value History

Halozyme Therapeutics News

Halozyme Therapeutics Company Life